Payer-centric post-launch studies for optimal negotiations
  • March 13, 2017
  • Valid Insight

Many healthcare stakeholders want to ensure better health outcomes for patients. However, many new and innovative therapies enter the market with evidence gaps in their value proposition. Since tracking and measuring outcomes entails cost and time, many payers decide to go with simpler and more straightforward financial-based contracting agreements, such as discounting, price-volume agreements, and […]

Formulary Lock Out
Formulary lock out in the US
  • January 29, 2017
  • Valid Insight

Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]

Understanding payer archetypes
  • January 24, 2017
  • Valid Insight

One-size-fits-all has become an outdated and non-recommendable approach in pharma business. During the period of blockbuster medical products, this approach was applicable – the wider drug developers cast their net, the greater the chances of expanding their market share. Another merit to this approach was that it made strategy development relatively less complex for pharma […]

Market Access
Valid News, Market Access Insights – Vol 01, Issue 01
  • January 17, 2017
  • Valid Insight

Valid News, Market Access Insights is our new newsletter. In Volume 01, Issue 01, we provide advice on how to weather pricing competition and prepare for reimbursement, as well as explain the role of confidential contracting for flexible pricing. The growing importance of patient-reported outcomes are also discussed. A global market access news round-up and […]